Status:
COMPLETED
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom n...
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options
- Aged 18 or over and a life expectancy of more than 12 weeks
Exclusion
- The last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy
- Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00358956
Start Date
August 1 2006
End Date
May 1 2014
Last Update
January 30 2017
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Little Rock, Arkansas, United States
2
Research Site
Boston, Massachusetts, United States
3
Research Site
St Leonards, Australia
4
Research Site
Sherbrooke, Quebec, Canada